title: [Clinical study on shenmai injection in promoting postoperative recovery in patients of breast cancer].
abstract: OBJECTIVE
  To investigate the effect of Shenmai injection in promoting postoperative recovery of patients with breast cancer.
  
  
  METHODS
  Eighty postoperative patients of breast cancer were selected and divided into two groups, the treated group (40 cases) was given intravenous Shenmai injection for 7 days and compared with the control group (40 cases) in wound healing time, postoperative drainage volume, complication and blood picture, and the NK cell, T-lymphocyte subsets (CD3, CD4, CD8), were compared before and after treatment.
  
  
  RESULTS
  The wound healing time and postoperational complication in the treated group were less than those in the control group significantly. There was no difference between the two groups in WBC and platelet count, but the recovery of hemoglobin in the treated group was quicker than that in the control group significantly (P < 0.05), as comparing with the control group, the NK cell, CD4, CD4/CD8 ratio in the treated group were elevated faster than those in the control group significantly (P < 0.05).
  
  
  CONCLUSIONS
  Shenmai injection was beneficial to the recovery of postoperative patients of breast cancer, to reducing the occurrence of complication and was favorable to conduct postoperative chemotherapy smoothly.
authors.affiliation: Breast Diseases Center, People's Hospital, Beijing Medical University, Beijing (100044).
authors.forename: P
authors.initials: P
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Cao
authors.forename: X
authors.initials: X
authors.lastname: Qiao
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D015409:Mastectomy, Radical; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011184:Postoperative Period
chemical_list: D004365:Drugs, Chinese Herbal; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate